Efficacy and safety of fluticasone propionate hydrofluoroalkane inhalation aerosol in pre-school-age children with asthma: A randomized, double-blind, placebo-controlled study

Journal of Pediatrics

Volumn 149, Issue 5, 2006, Pages

  Qaqundah, Paul Y ^a   Sugerman, Robert W ^a   Ceruti, Elaina ^a   Maspero, Jorge Fernando ^a   Kleha, Joseph F ^a   Scott, Catherine A ^a   Wu, Wei ^a   Mehta, Rashmi ^a   Crim, Courtney ^a  

^a Pediatric Medical Care Group Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CROMOGLYCATE DISODIUM; FLUORINATED HYDROCARBON; FLUTICASONE PROPIONATE; HYDROCORTISONE; LEUKOTRIENE RECEPTOR STIMULATING AGENT; NEDOCROMIL; PLACEBO; SALBUTAMOL; THEOPHYLLINE;

ARTICLE; ASTHMA; BRONCHITIS; CANDIDIASIS; CHICKENPOX; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FACE MASK; FEMALE; FEVER; FOOD ALLERGY; GASTROENTERITIS; HUMAN; HYDROCORTISONE URINE LEVEL; LACRIMATION; LUNG INFILTRATE; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; OTITIS MEDIA; PHARYNGITIS; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCORING SYSTEM; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SWELLING; SYMPTOM; THRUSH; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION; VOMITING;

EID: 33751109992     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2006.07.045     Document Type: Article

References (28)

1. Bloom B, Dey AN. Summary health statistics for US children: National Health Interview Survey, 2004. Vital Health Stat 2006, series 10, number 227. Available at: http://www.cdc.gov/nchs/data/series/sr_10/sr10_227.pdf. Accessed April 24, 2006.
2. Lemanske Jr. R.F. Inflammation in childhood asthma and other wheezing disorders. Pediatrics 109 (2002) 368-372
3. Flovent® (fluticasone propionate) inhalation aerosol prescribing information [package insert] (2006), GlaxoSmithKline February
4. Lyttle B., Gilles J., Panov M., Emeryk A., and Wixon C. Fluticasone propionate 100 μg bid using a non-CFC propellant, HFA 134a, in asthmatic children. Can Respir J 10 (2003) 103-109
5. Bisgaard H., Gillies J., Groenewald M., and Maden C. The effect of inhaled fluticasone propionate in the treatment of young asthmatic children: a dose comparison study. Am J Respir Crit Care Med 160 (1999) 126-131
6. Bisgaard H., Allen D., Milanowski J., Kalev I., Willits L., and Davies P. Twelve-month safety and efficacy of inhaled fluticasone propionate in children aged 1 to 3 years with recurrent wheezing. Pediatr 113 (2004) e87-e94
7. Teper A.M., Colom A.J., Kofman C.D., Maffey A.F., Vidaurreta S.M., and Bergada I. Effects of inhaled fluticasone propionate in children less than 2 years old with recurrent wheezing. Pediatr Pulmonol 37 (2004) 111-115
8. Wasserman R.L., Baker J.W., Kim K.T., Blake K.V., Scott C.A., Wu W., et al. Efficacy and safety of inhaled fluticasone propionate chlorofluorocarbon in 2- to 4-year-old patients with asthma: results of a double-blind, placebo-controlled study. Ann Asthma Allergy Imunol 96 (2006) 808-818
9. Bisgaard H. Delivery of inhaled medication to children. J Asthma 34 (1997) 443-467
10. Newhouse M.T. Are nebulizers obsolete for administering asthma medications to infants and children? [editorial]. Pediatr Pulmonol 15 (1993) 271-272
11. Practical guidelines for the diagnosis and management of asthma. Clinical practice guidelines of the American Academy of Pediatrics: a compilation of evidence-based guidelines for pediatric practice. 2nd ed. (1999), American Academy of Pediatrics, Elk Grove Village, IL 3-70
12. Global Initiative for Asthma: pocket guide for asthma management and prevention. Based on the workshop report: global strategy for asthma management and prevention. NIH Publication 02-3659, revised 2002.
13. National Asthma Education and Prevention Program. Guidelines for the diagnosis and management of asthma: update on selected topics, 2002. NIH Publication 02-5075, June 2002.
14. Mehta R, Collins D, Sheng-Fan S, Beerahee M, Daley-Yates P, Kunka R. Fluticasone propionate systemic exposure from a meterered dose inhaler with and without Aerochamber Plus spacer in pediatric asthma. Report presented at the American College of Clinical Pharmacology, 2005.
15. Mackie A.E., McDowall J.E., Ventresca P., Bye A., Falcoz C., and Daley-Yates P.T. Systemic exposure to fluticasone propionate administered via metered-dose inhaler containing chlorofluorocarbon or hydrofluoroalkane propellant. Clin Pharmacokinet 39 (2000) 17-22
16. Ayres J.G., Millar A.B., Sykes A.P., and UK study group. Clinical efficacy and safety of fluticasone propionate 1 mg twice daily administered via an HFA-134a pressurized metered dose inhaler to patients with severe asthma. Respir Med 94 (2000) S42-S50
17. Tonnel A.B., Bons J., Legendre M., Prud'Homme A., Bugnas B., Evano-Celli I., et al. Clinical efficacy and safety of fluticasone propionate 250 mcg twice daily administered via a HFA-134a pressurized metered dose inhaler to patients with mild to moderate asthma. Respir Med 94 (2000) S29-S34
18. Perruchoud A.P., Lundback B., Yigla M., Sykes A.P., and international study group. Clinical efficacy and safety of fluticasone propionate 1 mg per day administered via an HFA-134a pressurized metered-dose inhaler to patients with moderate to severe asthma. Respir Med 94 (2000) S35-S41
19. Lumry W.R., Conway M.M., LaForce C.F., Pearlman D.S., Scott C.A., Herje N.E., et al. Fluticasone propionate hydrofluoroalkane inhalation aerosol in patients receiving inhaled steroids. Ann Asthma Allergy Immunol 96 (2006) 51-59
20. Pinnas J.L., Noonan M.J., Weinstein S.F., Chervinsky P., Scott C.A., Herje N.E., et al. Fluticasone propionate HFA-134a pressurized metered-dose inhaler in adolescents and adults with moderate to severe asthma. J Asthma 42 (2005) 865-871
21. Carlsen K.C.L., Stick S., Kamin W., Cirule L., Hughes S., and Wixon C. The efficacy and safety of fluticasone propionate in very young children with persistent asthma symptoms. Respir Med 99; (2005) 1393-1402
22. 1 is associated with risk of asthma attacks in a pediatric population. J Allergy Clin Immunol 107 (2001) 61-67
23. Given J., Kent E., Gossage D., Clements D., Scott C., Wu W., et al. Safety of fluticasone propionate HFA in treating children 4-11 years of age with asthma [abstract]. J Allergy Clin Immunol 113 (2004)
24. Levy A., Condemi J., Landwehr L., Clements D., Scott C., Wu W., et al. Fluticasone propionate HFA improves asthma control in children aged 4 to 11 years with asthma [abstract]. J Allergy Clin Immunol 113 (2004)
25. Katz Y., Lebas F.X., Medley H.V., Robson R., and Fluticasone Propionate Study Group. Fluticasone propionate 50 mcg bid versus 100 mcg bid in the treatment of children with persistent asthma. Clin Ther 20 (1998) 424-437
26. Peden D.B., Berger W.E., Noonan M.J., Thomas M.R., Hendricks V.L., Hamedani A.G., et al. Inhaled fluticasone propionate delivered by means of two different multidose powder inhalers is effective and safe in a large pediatric population with persistent asthma. J Allergy Clin Immunol 102 (1998) 32-38
27. MacKenzie C.A., Weinberg E.G., Tabachnik E., Taylor M., Havnen J., and Crescenzi K. A placebo-controlled trial of fluticasone propionate in asthmatic children. Eur J Pediatr 152 (1993) 856-860
28. Hoekstra M.O., Grol M.H., Bouman K., Stijnen T., Koeter G.H., Kauffman H.F., et al. Fluticasone propionate in children with moderate asthma. Am J Respir Crit Care Med 154 (1996) 1039-1044